Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves’ hyperthyroidism undergoing radioiodine therapy: a randomized controlled study.

Summary

While radioiodine therapy is commonly used for treating Graves’ disease, a prolonged and clinical hypothyroidism may result in disabling symptoms leading to deterioration of quality of life (QoL) of patients. Introducing levothyroxine (LT4) treatment in the early post-therapeutic period may be an interesting approach to limit this phenomenon.